Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 8/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31508214 | 1.00 | FEN1 (0.39) | FEN1ALOX5APGPR119PDGFRBPDGFRA | |
| SCHEMBL31403617 | 0.92 | FEN1 (0.42) | FEN1ALOX5APPDGFRBPDGFRAPIM1 | |
| SCHEMBL31403629 | 0.92 | FEN1 (0.42) | FEN1ALOX5APPDGFRBPDGFRAPIM1 | |
| SCHEMBL31508259 | 0.80 | EPAS1 (0.35) | FEN1ALOX5AP | |
| SCHEMBL22663350 | 0.77 | PDGFRB (0.40) | GPR119PDGFRBPDGFRA | |
| SCHEMBL22663355 | 0.75 | PDGFRB (0.36) | GPR119PDGFRBPDGFRA | |
| SCHEMBL30748858 | 0.73 | KDM4E (0.44) | GPR119LOXLOXL2 | |
| SCHEMBL31508227 | 0.72 | FEN1 (0.44) | FEN1ALOX5AP | |
| SCHEMBL22663435 | 0.71 | CSF1R (0.42) | GPR119PDGFRBPDGFRA | |
| SCHEMBL32671842 | 0.70 | MAPT (0.40) | FEN1PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | FEN1 2255/4885ALOX5AP 4212/4885GPR119 861/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | FEN1 2661/4885ALOX5AP 4638/4885GPR119 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.